BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16900734)

  • 1. [Long-term effects of PUVA therapy on Israeli patients with vitiligo].
    Vussuki E; Ziv M; Rosenman D; David M
    Harefuah; 2006 Jul; 145(7):483-5, 552, 551. PubMed ID: 16900734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo.
    Parsad D; Kanwar AJ; Kumar B
    J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.
    Westerhof W; Nieuweboer-Krobotova L
    Arch Dermatol; 1997 Dec; 133(12):1525-8. PubMed ID: 9420536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoralen and ultraviolet A and narrow-band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study.
    Bhatnagar A; Kanwar AJ; Parsad D; De D
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1381-5. PubMed ID: 17958845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
    Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.
    Hearn RM; Kerr AC; Rahim KF; Ferguson J; Dawe RS
    Br J Dermatol; 2008 Sep; 159(4):931-5. PubMed ID: 18834483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in the treatment of vitiligo with oral khellin plus UVA.
    Hofer A; Kerl H; Wolf P
    Eur J Dermatol; 2001; 11(3):225-9. PubMed ID: 11358729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients.
    Radmanesh M; Saedi K
    J Dermatolog Treat; 2006; 17(3):151-3. PubMed ID: 16854754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic cutaneous effects of long-term psoralen and ultraviolet radiation therapy in patients with vitiligo.
    Harrist TJ; Pathak MA; Mosher DB; Fitzpatrick TB
    Natl Cancer Inst Monogr; 1984 Dec; 66():191-6. PubMed ID: 6531028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple keratoses and squamous carcinoma after PUVA treatment of vitiligo.
    Buckley DA; Rogers S
    Clin Exp Dermatol; 1996 Jan; 21(1):43-5. PubMed ID: 8689768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcipotriol and PUVA as treatment for vitiligo.
    Cherif F; Azaiz MI; Ben Hamida A; Ben O; Dhari A
    Dermatol Online J; 2003 Dec; 9(5):4. PubMed ID: 14996377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study.
    Yalçin B; Sahin S; Bükülmez G; Karaduman A; Atakan N; Akan T; Kölemen F
    J Am Acad Dermatol; 2001 Apr; 44(4):634-7. PubMed ID: 11260538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo.
    Wu CS; Lan CC; Wang LF; Chen GS; Wu CS; Yu HS
    Br J Dermatol; 2007 Jan; 156(1):122-9. PubMed ID: 17199578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of melanoma in association with long-term exposure to PUVA.
    Stern RS;
    J Am Acad Dermatol; 2001 May; 44(5):755-61. PubMed ID: 11312420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study.
    Bhatnagar A; Kanwar AJ; Parsad D; De D
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):638-42. PubMed ID: 17447977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of vitiligo with broadband ultraviolet B and vitamins.
    Don P; Iuga A; Dacko A; Hardick K
    Int J Dermatol; 2006 Jan; 45(1):63-5. PubMed ID: 16426381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
    Stern RS;
    J Am Acad Dermatol; 2012 Apr; 66(4):553-62. PubMed ID: 22264671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of vitiligo with oral methoxsalen and UVA.
    Lassus A; Halme K; Eskelinen A; Ranki A; Puska P; Salo O
    Photodermatol; 1984 Aug; 1(4):170-3. PubMed ID: 6531291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation.
    Abdel-Naser MB; Hann SK; Bystryn JC
    Arch Dermatol; 1997 Dec; 133(12):1530-3. PubMed ID: 9420537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study.
    Sapam R; Agrawal S; Dhali TK
    Int J Dermatol; 2012 Sep; 51(9):1107-15. PubMed ID: 22909369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.